Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus OXTRIPHYLLINE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOMETER versus OXTRIPHYLLINE PEDIATRIC.
BRONKOMETER vs OXTRIPHYLLINE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator